Cyclacel Pharmaceuticals (CYCC) vs. Zoetis (ZTS) Financial Contrast

Cyclacel Pharmaceuticals (NASDAQ:CYCC) and Zoetis (NYSE:ZTS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Cyclacel Pharmaceuticals and Zoetis, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclacel Pharmaceuticals 0 0 3 0 3.00
Zoetis 0 4 8 0 2.67

Cyclacel Pharmaceuticals currently has a consensus price target of $7.08, suggesting a potential upside of 887.64%. Zoetis has a consensus price target of $100.83, suggesting a potential upside of 1.82%. Given Cyclacel Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Cyclacel Pharmaceuticals is more favorable than Zoetis.

Volatility and Risk

Cyclacel Pharmaceuticals has a beta of 3.51, suggesting that its share price is 251% more volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.

Earnings and Valuation

This table compares Cyclacel Pharmaceuticals and Zoetis’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cyclacel Pharmaceuticals $150,000.00 82.24 -$7.29 million ($0.62) -1.16
Zoetis $5.83 billion 8.15 $1.43 billion $3.13 31.64

Zoetis has higher revenue and earnings than Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.


This table compares Cyclacel Pharmaceuticals and Zoetis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cyclacel Pharmaceuticals N/A -41.13% -33.11%
Zoetis 24.51% 73.85% 15.83%

Insider & Institutional Ownership

2.9% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.8% of Zoetis shares are owned by institutional investors. 1.5% of Cyclacel Pharmaceuticals shares are owned by insiders. Comparatively, 0.3% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


Zoetis pays an annual dividend of $0.66 per share and has a dividend yield of 0.7%. Cyclacel Pharmaceuticals does not pay a dividend. Zoetis pays out 21.1% of its earnings in the form of a dividend. Zoetis has increased its dividend for 5 consecutive years.


Zoetis beats Cyclacel Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

About Zoetis

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices and genetics. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with's FREE daily email newsletter.